{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:58:05Z","timestamp":1759481885155,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T00:00:00Z","timestamp":1394496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/nrneph.2014.37","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T11:59:04Z","timestamp":1394539144000},"page":"245-247","source":"Crossref","is-referenced-by-count":6,"title":["Is there a role for rituximab in nephrotic syndrome?"],"prefix":"10.1038","volume":"10","author":[{"given":"John","family":"Feehally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,11]]},"reference":[{"doi-asserted-by":"publisher","unstructured":"Ruggenenti, P.  et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. \n                    http:\/\/dx.doi.org\/10.1681\/ASN.2013030251\n                    \n                  .","key":"BFnrneph201437_CR1","DOI":"10.1681\/ASN.2013030251"},{"key":"BFnrneph201437_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","volume":"12","author":"AG Kattah","year":"2013","unstructured":"Kattah, A. G., Fervenza, F. C. & Roccatello, D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun. Rev. 12, 854\u2013859 (2013).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneph201437_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani, P.  et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308\u20131315 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201437_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco, A.  et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 23, 1117\u20131124 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201437_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MNH.0b013e3283522ea8","volume":"21","author":"RJ Glassock","year":"2012","unstructured":"Glassock, R. J. The pathogenesis of membranous nephropathy: evolution and revolution. Curr. Opin. Nephrol. Hypertens. 21, 235\u2013242 (2012).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"doi-asserted-by":"publisher","unstructured":"Cara-Fuentes, G.  et al. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr. Nephrol. \n                    http:\/\/dx.doi.org\/10.1007\/s00467-013-2534-4\n                    \n                  .","key":"BFnrneph201437_CR6","DOI":"10.1007\/s00467-013-2534-4"},{"key":"BFnrneph201437_CR7","first-page":"85ps21","volume":"3","author":"AC Chan","year":"2011","unstructured":"Chan, A. C. Rituximab's new therapeutic target: the podocyte actin cytoskeleton. Sci. Transl. Med. 3, 85ps21 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneph201437_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrneph.2012.141","volume":"8","author":"JW Gregersen","year":"2012","unstructured":"Gregersen, J. W. & Jayne, D. R. B-cell depletion in the treatment of lupus nephritis. Nat. Rev. Nephrol. 8, 505\u2013514 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201437_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks, U.  et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417\u2013427 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201437_CR10","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony, H. P.  et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res. Ther. 13, R75 (2011).","journal-title":"Arthritis Res. Ther."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.37","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2014.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:44:43Z","timestamp":1684471483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2014.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,11]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFnrneph201437"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2014.37","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2014,3,11]]}}}